Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ER121

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

University of Pennsylvania

Drug class:

HER2 inhibitor, EGFR C797S inhibitor

Related drugs:

‹

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

trastuzumab (369)

lapatinib (105)

neratinib (102)

trastuzumab-pkrb (23)

margetuximab (18)

poziotinib (16)

trastuzumab-dttb (11)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

mobocertinib (7)

Zercepac (trastuzumab biosimilar) (7)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

pertuzumab/trastuzumab/hyaluronidase-zzxf (2)

Hercease (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

›

HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	ER121 Sensitive: D – Preclinical ER121 Sensitive : D	ER121 Sensitive: D – Preclinical ER121 Sensitive : D
EGFR mutation	Solid Tumor	EGFR mutation	Solid Tumor	ER121 Sensitive: D – Preclinical ER121 Sensitive : D	ER121 Sensitive: D – Preclinical ER121 Sensitive : D